What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Schizophrenia
- Psychiatry
Donald C. Goff mainly focuses on Schizophrenia, Psychosis, Internal medicine, Psychiatry and Neuroscience.
His Schizophrenia research incorporates elements of NMDA receptor, Recall and Cognition.
His research in Psychosis intersects with topics in Clozapine, Audiology, Memoria, Clinical psychology and Cognitive disorder.
His Internal medicine research is multidisciplinary, incorporating perspectives in Diabetes mellitus, Endocrinology, Placebo and Gastroenterology.
His Placebo research is multidisciplinary, incorporating elements of Anesthesia, Randomized controlled trial and Abstinence.
He interconnects Clinical trial, Disease and Intensive care medicine in the investigation of issues within Psychiatry.
His most cited work include:
- Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. (935 citations)
- The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia (782 citations)
- Regionally Localized Thinning of the Cerebral Cortex in Schizophrenia (775 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Schizophrenia, Psychiatry, Psychosis, Internal medicine and Neuroscience.
His Schizophrenia research includes themes of Placebo, Cognition and Clinical psychology.
His work carried out in the field of Placebo brings together such families of science as Anesthesia and Positive and Negative Syndrome Scale.
His Psychiatry study combines topics in areas such as Clinical trial and Epidemiology.
His Psychosis research is multidisciplinary, relying on both NMDA receptor, Developmental psychology, Hippocampal formation, Hippocampus and Cognitive disorder.
His research integrates issues of Risperidone, Endocrinology, Olanzapine and Atypical antipsychotic in his study of Internal medicine.
He most often published in these fields:
- Schizophrenia (54.43%)
- Psychiatry (35.78%)
- Psychosis (33.64%)
What were the highlights of his more recent work (between 2012-2021)?
- Schizophrenia (54.43%)
- Psychiatry (35.78%)
- Internal medicine (31.50%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Schizophrenia, Psychiatry, Internal medicine, Placebo and Neuroscience.
His Schizophrenia study integrates concerns from other disciplines, such as Biomarker, Psychosis, Clinical trial and Clinical psychology.
His study in Psychosis is interdisciplinary in nature, drawing from both Hippocampal formation, Molecular biology and Psychological intervention.
His Psychiatry study which covers Adverse effect that intersects with Fluphenazine, Social stress and Acute intoxication.
His Internal medicine research incorporates elements of Risperidone, Relapse prevention and Endocrinology.
His Placebo research includes themes of Psychopathology, Scale for the Assessment of Negative Symptoms, Brief Psychiatric Rating Scale, Pharmacology and Positive and Negative Syndrome Scale.
Between 2012 and 2021, his most popular works were:
- Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. (136 citations)
- Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles (103 citations)
- The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia (86 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Schizophrenia
- Psychiatry
Donald C. Goff focuses on Schizophrenia, Psychiatry, Placebo, Internal medicine and Randomized controlled trial.
The concepts of his Schizophrenia study are interwoven with issues in Psychosis, Prefrontal cortex, Clinical psychology and Neuroscience, Brain mapping.
Donald C. Goff is studying Schizoaffective disorder, which is a component of Psychiatry.
The Placebo study which covers Scale for the Assessment of Negative Symptoms that intersects with Vitamin B12 and Surgery.
He interconnects Gastroenterology, Allele and Positive and Negative Syndrome Scale in the investigation of issues within Internal medicine.
His Randomized controlled trial research is multidisciplinary, incorporating elements of Clozapine, Discontinuation, Relapse prevention, Risperidone and Antipsychotic.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
